ArticleCancer medicine2019

Real-world outcomes of NSCLC patients receiving tissue or circulating tumor DNA-guided osimertinib treatment.

Po-Lan Su et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.